May 23, 2023

Office of the Attorney General
State of Vermont

via email to: AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A.§4637(c), Biogen is hereby providing additional information related to the 3-day notice of the introduction of a new prescription drug in the commercial market as submitted on April 27, 2023:

NDC	Description	Date Commercially Available	Wholesale Acquisition Cost (WAC)*
64406-0109-01	QALSODY is supplied one vial per carton as follows: 100 mg/15 mL (6.7 mg/mL) single-dose vial	04/25/2023	$14,230.00

**Price to wholesalers, without regard to prompt pay or other discounts, rebates, chargebacks, or any fees paid to wholesalers for services performed. Does not represent prices charged to other customers or classes of trade.*

Additional information:

Requested Information	Biogen Submission
A description of the marketing and pricing plans used in the launch of the new drug in the United States and Internationally	QALSODY will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences. Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients, 2. Present and Future Benefit to Society, 3. Fulfilling our commitment to Innovation, 4. Evolution toward Value Based Care, and 5. Affordability & Sustainability. Further information can be found at: https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf

Requested Information	Biogen Submission
The estimated volume of patients who may be prescribed the drug	330 QALSODY ™ (tofersen) is a 100 mg/15 mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. The estimated number of patients provided is the number of people in the U.S. living with the disease. As of the time of this submission, Biogen is unable to estimate the volume of patients who will be prescribed QALSODY.
Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	QALSODY was not granted breakthrough therapy designation. QALSODY was granted priority review.
The date and price of acquisition if the drug was not developed by the manufacturer	N/A

Please let me know if you need any additional information.

Best Regards,

Sooah Cheung
Associate Director, Contracts & Pricing Governance
Biogen | 133 Boston Post Road, 17-307 | Weston, MA | 02493
Email: sooah.cheung@biogen.com | Direct: 781-464-1606